764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study

J Baum,B.D Nguyen,P Meyer-Wilmes,A Kreklau,C Buschmann,S Boz,C Fotopoulou,R Chekerov,E.I Braicu,M Hummel,J Sehouli,K Pietzner

doi:10.1016/j.annonc.2021.08.1206

764P Survey on the practical implementation of BRCA gene and HRD-testing and PARP-inhibitor management in Germany: A national NOGGO/JAGO-AGO intergroup study

J Baum, B.D Nguyen + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1206

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Charité - Universitätsmedizin Berlin, University Hospital of Zurich, RWTH Aachen University, University Hospital Leipzig, LMU Klinikum, Ludwig-Maximilians-Universität München, Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Imperial College London

#Management In Germany #High Grade Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Since the introduction of Poly (ADP-ribose) polymerase inhibitors (PARPi) the Breast Cancer gene (BRCA)-testing has evolved as a standard management in high grade ovarian cancer (EOC). The purpose of the study is to analyze the current implementation of BRCA testing and PARPi therapy for EOC in Germany.

Full Text